Received Apr 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| DTAP | DTAP (INFANRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| DTAPIPV | DTAP + IPV (KINRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| FLU3 | INFLUENZA (SEASONAL) (FLULAVAL) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| HEP | HEP B (ENGERIX-B) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | UNK | — | — |
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | — | — |
Possible administration of vaccines after temperature excursion; This non-serious case was reported by a physician via call center representative and described the occurrence of incorrect storage of drug in a patient who received Men B NVS (Bexsero) for prophylaxis. Co-suspect products included DTPa (Reduced antigen) (Boostrix) for prophylaxis, HBV (Engerix B) for prophylaxis, Flu Seasonal TIV Quebec (Flulaval) for prophylaxis, DTPa (Infanrix) for prophylaxis and DTPa-IPV (Kinrix) for prophylaxis. On an unknown date, the patient received Bexsero, Boostrix, Engerix B, Flulaval, Infanrix and Kinrix. On an unknown date, an unknown time after receiving Bexsero, Boostrix, Engerix B, Flulaval, Infanrix and Kinrix, the patient experienced incorrect storage of drug (Verbatim: Possible administration of vaccines after temperature excursion). The outcome of the incorrect storage of drug was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 03-APR-2025 The doctor called to report Bexsero, Boostrix, Engerix-B, Flulaval, Infanrix, Kinrix experienced a temperature excursion at 24.2°F for 14 hours and after that was possible some of the vaccines were administered but did not had any more information, which led to incorrect storage of drug. The Vaccine Administration Facility was the same as Primary Reporter.